indications for glp-1 agonists Receptor GLP-1 and Incretin-Based Therapies in
Description
This program was established to test how a category of drugs for weight management becoming available under Medicare might impact beneficiaries and the Medicare program
Central nervous system engagement introduces risks of mood alteration, cognitive effects, and behavioral changes, necessitating careful dose titration and patient monitoring
Mounjaros 20% average is meaningfully higher than the oral GLP-1 range
Ye et al
GLP-1 receptors are found throughout the body and within the brain and can have multi-system effects, including our reward-based eating
Bupropion may increase the risk of suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment
